Business context and reporting period
Entity discrepancy: The supplied filing is GlycoMimetics, Inc. (Nasdaq: GLYC), not Crescent BioPharma, Inc. It is a Form 10-Q for the quarter ended September 30, 2022, filed November 9, 2022.
GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates. Its lead candidate, uproleselan, is being studied with chemotherapy for relapsed/refractory acute myeloid leukemia (AML). The company has no approved products and has not generated product-sale revenue.
Financial results and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $86,560 | $75,000 | $1.14 million |
| Research and development expense | $4.92 million | $13.28 million | $22.50 million | $34.60 million |
| General and administrative expense | $3.84 million | $4.14 million | $14.36 million | $12.57 million |
| Net loss | $8.52 million | $17.33 million | $36.44 million | $46.01 million |
| Net loss per share | $0.16 | $0.34 | $0.70 | $0.90 |
As of September 30, 2022, cash and cash equivalents were $51.62 million, down from $90.25 million at December 31, 2021. Total assets were $55.96 million; total liabilities were $7.84 million, including $1.18 million of lease liabilities. The filing reports no debt borrowings. Stockholders’ equity was $48.12 million, and accumulated deficit was $409.34 million.
For the first nine months of 2022, operating cash use was $38.55 million, investing cash use was $84,000, and financing cash flow was zero. Cash declined by $38.63 million. The company reported no operating margin measure; with minimal collaboration revenue and substantial operating expenses, it remained loss-making.
Changes versus the prior comparable period
- Nine-month revenue fell 93% to $75,000, mainly because the comparable 2021 period included $1.1 million from clinical-supply sales to Apollomics. No such supply revenue was recognized in 2022.
- Nine-month R&D expense declined 35%, primarily due to lower uproleselan clinical-development and manufacturing costs after trial enrollment was completed in 2021.
- Nine-month G&A expense rose 14%, reflecting uproleselan commercial-startup costs, higher patent fees and additional personnel costs, partly offset by lower stock-based compensation.
- Nine-month net loss narrowed by about 21%. Operating cash use also declined, while 2021 included $9.58 million of financing proceeds from stock sales.
Outlook, risks and notable items
- Liquidity and going concern: Management estimated existing cash would fund operations to the end of 2023, excluding potential financing or business-development proceeds. Separately, it stated that forecast negative cash flows and the lack of committed financing create substantial doubt about the company’s ability to continue as a going concern beyond one year from issuance without additional financing.
- The company had no committed external funding. It could sell up to $100 million of common stock under its 2022 at-the-market agreement, but had made no sales under it through the filing’s issuance date. Additional capital may be unavailable or could dilute shareholders; failure to raise funds could force delays, reductions or termination of programs.
- Uproleselan trial timing: The company expected the Phase 3 trial to reach 80% of survival events by the end of 2022 for an independent Data Monitoring Committee review. Depending on the committee’s recommendation, top-line results could be available in the first half of 2023, or after the survival-event trigger then projected around year-end 2023. These are expectations, not assured outcomes.
- The company reported completing enrollment in the Phase 2 portion of an NCI Phase 2/3 trial in December 2021. It also reported an IND for GMI-1687 had received FDA clearance to proceed and said it was seeking a licensing partner. GMI-1359 was no longer actively being developed; its IND was deactivated in August 2022.
- COVID-19 and emerging variants could affect trial completion timing. The company also disclosed Nasdaq’s May 2022 notice that its share price had failed the $1.00 minimum-bid-price requirement; the stated compliance deadline was November 28, 2022, with delisting risk if compliance was not restored.
- There were no material legal proceedings reported. Management said disclosure controls were effective as of September 30, 2022, and that no material changes to internal control over financial reporting occurred during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: the supplied document is GlycoMimetics’ filing, not Crescent BioPharma’s.
- Check subsequent updates on financing, cash runway and the going-concern assessment, including any use of the $100 million ATM facility.
- Verify the uproleselan Data Monitoring Committee review, survival-event timing and subsequent trial results or regulatory actions.
- Confirm whether GlycoMimetics regained Nasdaq’s minimum-bid-price compliance by the stated deadline and whether any listing action followed.
- Monitor Apollomics development progress and any resulting milestone, supply or royalty revenue; those payments are conditional and uncertain.